News
BMY-RT
0.6901
-42.97%
-0.5199
J&J, Bristol Myers lose challenges to US drug price negotiation program
J&J, Bristol Myers lose challenges to US drug price program. A U.S. Judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the law. The law requires them to lower prices of their blood clot prevention drugs with Medicare. The program aims to save $25 billion in drug costs annually.
Reuters · 5h ago
LIVE MARKETS-Rates, the Fed, AI among key themes this earnings season
Rates, the Fed, AI among key themes this earnings season. Main U.S. Indexes green; Nasdaq out front. First-quarter S&P 500 earnings are expected to have risen 5.6% from the year-ago quarter. Analysts say earnings are beating expectations by more than the average.
Reuters · 9h ago
BRISTOL-MYERS SQUIBB CO - UNDER TERMS OF AGREEMENT, REPERTOIRE WILL RECEIVE UP TO $1.8 BLN FOR ACHIEVING DEVELOPMENT, REGULATORY COMMERCIAL MILESTONES
Reuters · 17h ago
UPDATE 1-S&P 500 Q1 earnings estimated growth improves; stocks up for week
S&P 500 year-over-year earnings growth for the first quarter of 2024 is seen at 5.6%, up from 4.3% last week. About 78% of first-quarter estimated earnings for S&p 500 companies are beating expectations. Stocks are up more than 2% for the week but are still down 2% since March.
Reuters · 3d ago
LIVE MARKETS-With the season in full swing Q1 earnings view improves
With the season in full swing Q1 earnings view improves U.S. Equity indexes rise. Wall Street is expecting earnings growth of 5.6% for the quarter, up from 4.3% on Thursday. 229 of the benchmark S&P 500 companies have reported first quarter results.
Reuters · 3d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: BARCLAYS CUTS TARGET PRICE TO $43 FROM $51
Reuters · 3d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: BMO CUTS TARGET PRICE TO $48 FROM $55
Reuters · 3d ago
CHMP ADOPTS POSITIVE OPINION RECOMMENDING APPROVAL OF BRISTOL MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) IN COMBINATION WITH CISPLATIN AND GEMCITABINE FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA
Reuters · 3d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $64 FROM $68
Reuters · 3d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: JP MORGAN CUTS TARGET PRICE TO $60 FROM $65
Reuters · 3d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: JEFFERIES CUTS TARGET PRICE TO $54 FROM $56
Reuters · 3d ago
UPDATE 1-S&P 500 first-qtr earnings outlook improves this week -LSEG
U.S. First-quarter earnings growth estimate for S&P 500 has improved in recent days. Year-over-year growth for the first quarter of 2024 is seen at 4.3%, up from 3.3% this week. But disappointing forecasts from Meta Platforms have offset some of the optimism.
Reuters · 4d ago
Bristol-Myers Squibb Co reports results for the quarter ended in March - Earnings Summary
Bristol-Myers Squibb Co reports results for the quarter ended in March. The company reported a quarterly adjusted loss of $4.40 per share. Revenue rose 4.7% to $11.87 billion from the same quarter last year. Bristol- myers squibb shares have fallen by 9.9% this quarter.
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Loar, Regeneron, Intel
U.S. Stocks slumped on Thursday. Dow Jones Industrial Average was down 1.15% and the S&P 500 was down 0.76%. Most megacaps fell after Meta Platforms' quarterly results. Newmont Corp. Was the top percentage gainer on the NYSE and the Nasdaq.
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Viking, Alphabet, Dover
U.S. Stocks were sharply lower on Thursday. The Dow Jones Industrial Average was down 1.58% and the S&P 500 and Nasdaq Composite were also down. Meta Platforms dropped 12.7% after dour quarterly results. Newmont Corp was the top percentage gainer on the S.P. 500 and the Nasdaq.
Reuters · 4d ago
BUZZ-Bristol Myers hits over four-year low after co swings to loss
Shares of drugmaker Bristol Myers Squibb fall 7.50% to hit over four-year low of $45.20. Co posts Q1 loss of $4.40/shr. Company slashes annual profit outlook due to charges related to recent acquisitions.
Reuters · 4d ago
BRISTOL-MYERS SHARES DOWN ABOUT 4% AFTER CO SWINGS TO QUARTERLY LOSS, SLASHES 2024 PROFIT FORECAST
Reuters · 4d ago
BRISTOL-MYERS SHARES EXTEND LOSSES, LAST DOWN 7.5%
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, Valero Energy, Union Pacific
Dow e-minis were down 1.14% in early trading. Chipotle Mexican Grill, Valero Energy, Union Pacific among top U.S. Stocks on the move. Meta Platforms down 15.3% after dour quarterly results. Sign of persistent inflation dampens hopes of Federal Reserve cutting interest rates.
Reuters · 4d ago
BRISTOL-MYERS EXEC SAYS CO "NOW IN A MUCH STRONGER POSITION TO MEET DEMAND" FOR BREYANZI
Reuters · 4d ago
More
Webull provides a variety of real-time BMY-RT stock news. You can receive the latest news about Bristol-Myers through multiple platforms. This information may help you make smarter investment decisions.
About BMY-RT
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.